Tyra Biosciences (NASDAQ:TYRA) Trading Down 3.3%

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating)’s share price traded down 3.3% during trading on Thursday . The stock traded as low as $8.83 and last traded at $9.02. 52,316 shares were traded during trading, a decline of 41% from the average session volume of 88,450 shares. The stock had previously closed at $9.33.

Analyst Ratings Changes

Separately, HC Wainwright began coverage on Tyra Biosciences in a research report on Thursday, June 23rd. They set a “buy” rating and a $12.00 target price on the stock.

Tyra Biosciences Stock Performance

The stock’s 50 day simple moving average is $8.13 and its 200 day simple moving average is $9.66.

Tyra Biosciences (NASDAQ:TYRA – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.16). On average, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

Institutional investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of Tyra Biosciences in the 4th quarter worth $39,000. New York State Common Retirement Fund bought a new position in Tyra Biosciences during the first quarter valued at about $113,000. Rhumbline Advisers bought a new position in Tyra Biosciences during the first quarter valued at about $125,000. Bailard Inc. bought a new position in Tyra Biosciences during the second quarter valued at about $92,000. Finally, Bank of New York Mellon Corp grew its position in Tyra Biosciences by 48.8% during the first quarter. Bank of New York Mellon Corp now owns 30,620 shares of the company’s stock valued at $328,000 after buying an additional 10,045 shares during the period. Institutional investors own 99.96% of the company’s stock.

Tyra Biosciences Company Profile

(Get Rating)

Tyra Biosciences, Inc, a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.